William Hinshaw Net Worth

The estimated Net Worth of William Hinshaw is at least $1.75 Million dollars as of 17 October 2022. Mr. Hinshaw owns over 16,000 units of Axcella Health Inc stock worth over $375,615 and over the last 5 years he sold AXLA stock worth over $24,960. In addition, he makes $1,345,530 as President, Chief Executive Officer, and Director at Axcella Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hinshaw AXLA stock SEC Form 4 insiders trading

William has made over 3 trades of the Axcella Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 16,000 units of AXLA stock worth $24,960 on 17 October 2022.

The largest trade he's ever made was exercising 50,000 units of Axcella Health Inc stock on 28 January 2022 worth over $229,000. On average, William trades about 8,788 units every 29 days since 2019. As of 17 October 2022 he still owns at least 82,012 units of Axcella Health Inc stock.

You can see the complete history of Mr. Hinshaw stock trades at the bottom of the page.

William Hinshaw biography

William Hinshaw serves as President, Chief Executive Officer, Director of the Company. Prior to joining us, Mr. Hinshaw served in increasing roles of responsibility at Novartis Pharmaceuticals Corporation, a pharmaceutical company, from December 2003 until November 2017, most recently as the Executive Vice President and Head of U.S. Oncology. Mr. Hinshaw holds a B.S. in molecular biology from the University of Wisconsin.

What is the salary of William Hinshaw?

As the President, Chief Executive Officer, and Director of Axcella Health Inc, the total compensation of William Hinshaw at Axcella Health Inc is $1,345,530. There are 2 executives at Axcella Health Inc getting paid more, with Shreeram Aradhye having the highest compensation of $3,911,720.

How old is William Hinshaw?

William Hinshaw is 51, he's been the President, Chief Executive Officer, and Director of Axcella Health Inc since 2018. There are 12 older and 5 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.

What's William Hinshaw's mailing address?

William's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., P.O. BOX 1270, LITTLETON, MA, 01460.

Insiders trading at Axcella Health Inc

Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa..., and Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.

What does Axcella Health Inc do?

axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.

Complete history of Mr. Hinshaw stock trades at Axcella Health Inc

Axcella Health Inc executives and stock owners

Axcella Health Inc executives and other stock owners filed with the SEC include:

• Shreeram Aradhye,
  Executive Vice President, Chief Development Officer
• Manu Chakravarthy,
  Senior Vice President, Chief Medical Officer
• William Hinshaw,
  President, Chief Executive Officer, Director
• David Epstein,
  Chairman of the Board
• William R. Hinshaw Jr.,
  Pres, CEO & Director
• Laurent Chardonnet,
  Consultant
• William Baird,
  Independent Director
• Catherine Sohn,
  Independent Director
• Gary Pisano,
  Independent Director
• Gregory Behar,
  Independent Director
• Cristina Rondinone,
  Independent Director
• Stephen Hoge,
  Independent Director
• Stephen Mitchener,
  Senior Vice President, Chief Business Officer
• Paul Fehlner,
  Senior Vice President, Chief Intellectual Property Officer
• Heidy King-Jones,
  Senior Vice President of Legal, General Counsel
• Tony Tramontin,
  Senior Vice President of Research and Development , Chief Scientific Officer
• Laurent Chardonnet,
  Chief Financial Officer, Senior Vice President
• Karim Azer Ph.D.,
  VP of Systems Biology & Discovery
• Dr. Margaret Koziel M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Alison D. Schecter M.D.,
  Pres of R&D
• Dr. Larry Bell,
  Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP
• Virginia R. Dean,
  Sr. VP & Chief People Officer
• Dr. Paul Fehlner J.D., Ph.D.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Jason Fredette,
  VP of Investor Relations & Corp. Communications
• Health Science Us Holdings,...,
  
• Michael Rosenblatt,
  Director
• David A Berry,
  Director
• Ventures Fund Iv General Pa...,
  
• Paul J Sekhri,
  Director
• Ventures Fund Iv General Pa...,
  
• Des Produits Nestle S.A.Nes...,
  
• Alison D. Schecter,
  President - Research & Dev.
• Virginia R Dean,
  SVP, Chief People Officer
• Margaret Koziel,
  Chief Medical Officer
• Ventures Fund Iv General Pa...,
  
• Robert Crane,
  Chief Financial Officer
• Torben Straight Nissen,
  Director
• Robert L. Rosiello,
  Director